Rising Biosciences (Rising Biosciences) Return-on-Tangible-Equity : 0.00% (As of . 20)

View and export this data going back to . Start your Free Trial

What is Rising Biosciences Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Rising Biosciences's annualized net income for the quarter that ended in . 20 was $ Mil. Rising Biosciences's average shareholder tangible equity for the quarter that ended in . 20 was $ Mil. Therefore, Rising Biosciences's annualized Return-on-Tangible-Equity for the quarter that ended in . 20 was %.

The historical rank and industry rank for Rising Biosciences's Return-on-Tangible-Equity or its related term are showing as below:

RBII's Return-on-Tangible-Equity is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 6.265
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Rising Biosciences Return-on-Tangible-Equity Historical Data

The historical data trend for Rising Biosciences's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rising Biosciences Return-on-Tangible-Equity Chart

Rising Biosciences Annual Data

Trend

Return-on-Tangible-Equity

Rising Biosciences Quarterly Data

Return-on-Tangible-Equity

Competitive Comparison of Rising Biosciences's Return-on-Tangible-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Rising Biosciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rising Biosciences's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rising Biosciences's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Rising Biosciences's Return-on-Tangible-Equity falls into.

Rising Biosciences Return-on-Tangible-Equity Calculation

Rising Biosciences's annualized Return-on-Tangible-Equity for the fiscal year that ended in . 20 is calculated as

Return-on-Tangible-Equity	=	Net Income	/	( (Total Tangible Equity	+	Total Tangible Equity)	/ count )
		(A: . 20 )		(A: . 20 )		(A: . 20 )
	=	Net Income	/	( (Total Stockholders Equity - Intangible Assets	+	Total Stockholders Equity - Intangible Assets )	/ count )
		(A: . 20 )		(A: . 20 )		(A: . 20 )
	=		/	( (	+	)	/ )
	=		/
	=	%

Rising Biosciences's annualized Return-on-Tangible-Equity for the quarter that ended in . 20 is calculated as

Return-on-Tangible-Equity	=	Net Income	/	( (Total Tangible Equity	+	Total Tangible Equity)	/ count )
		(Q: . 20 )		(Q: . 20 )		(Q: . 20 )
	=	Net Income	/	( (Total Stockholders Equity - Intangible Assets	+	Total Stockholders Equity - Intangible Assets)	/ count )
		(Q: . 20 )		(Q: . 20 )		(Q: . 20 )
	=		/	( (	+	)	/ )
	=		/
	=	%

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (. 20) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

Rising Biosciences (GREY:RBII) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.

Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.

Rising Biosciences Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Rising Biosciences's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Rising Biosciences (Rising Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rising Biosciences Inc (GREY:RBII) » Definitions » Return-on-Tangible-Equity

Traded in Other Exchanges

N/A

Address

1180 Cleveland Road, Sandusky, OH, USA, 44870

Website

http://www.risingbiosciences.com

Rising Biosciences Inc is a United States-based company engaged in research and development activities. It is focused on oral and topical cannabis and non-cannabis based pharmaceuticals. The company seeks to address the market demand for the treatment of the danger of opiates, whose long-term effects can include liver damage, addiction and brain damage due to hypoxia, resulting from respiratory depression, among other complications.